Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).

Vasey, P A; Bissett, D; Strolin-Benedetti, M; Poggesi, I; Breda, M; Adams, L; Wilson, P; Pacciarini, M A; Kaye, S B; Cassidy, J

Vasey, P A; Bissett, D; Strolin-Benedetti, M; Poggesi, I; Breda, M; Adams, L; Wilson, P; Pacciarini, M A; Kaye, S B; Cassidy, J.

Affiliation

Vasey PA; Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom.

Cancer Res ; 55(10): 2090-6, 1995 May 15.

Article in En | MEDLINE | ID: mdl-7743508

Subject(s)

Doxorubicin/analogs & derivatives; Neoplasms/drug therapy; Adult; Aged; Doxorubicin/adverse effects; Doxorubicin/pharmacokinetics; Doxorubicin/therapeutic use; Female; Humans; Liver/drug effects; Male; Middle Aged; Neoplasms/metabolism; Neutropenia/chemically induced; Thrombocytopenia/chemically induced

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Res Year: 1995 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links